Journal
EXPERIMENTAL DERMATOLOGY
Volume 28, Issue 3, Pages 219-224Publisher
WILEY
DOI: 10.1111/exd.13887
Keywords
alpha-melanocyte-stimulating hormone; cutaneous wound healing; melanocortin-1 receptor; melanocortins
Categories
Funding
- Deutsche Forschungsgemeinschaft [BO 1075/8-3]
Ask authors/readers for more resources
Cutaneous wound healing is a complex process divided into different phases, that is an inflammatory, proliferative and remodelling phase. During these phases, a variety of resident skin cell types but also cells of the immune system orchestrate the healing process. In the last year, it has been shown that the majority of cutaneous cell types express the melanocortin 1 receptor (MC1R) that binds alpha-melanocyte-stimulating hormone (alpha-MSH) with high affinity and elicits pleiotropic biological effects, for example modulation of inflammation and immune responses, cytoprotection, antioxidative defense and collagen turnover. Truncated alpha-MSH peptides such as Lys-Pro-Val (KPV) as well as derivatives like Lys-D-Pro-Thr (KdPT), the latter containing the amino acid sequence 193-195 of interleukin-1 beta, have been found to possess anti-inflammatory effects but to lack the pigment-inducing activity of alpha-MSH. We propose here that such peptides are promising future candidates for the treatment of cutaneous wounds and skin ulcers. Experimental approaches in silico, in vitro, ex vivo and in animal models are outlined. This is followed by an unbiased discussion of the pro and contra arguments of such peptides as future candidates for the therapeutic management of cutaneous wounds and a review of the so-far available data on melanocortin peptides and derivatives in wound healing.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available